Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study

Abstract

OBJECTIVES: To evaluate pregabalin's efficacy and safety versus placebo to reduce pain in patients with diabetic peripheral neuropathy (DPN) using a concomitant nonsteroidal anti-inflammatory drug. MATERIALS AND METHODS: In a randomized, double-masked, 14-week, 2-period, crossover study, patients with painful DPN using a nonsteroidal anti-inflammatory drug for non-DPN-related pain received 150 to 300 mg/d pregabalin or placebo (period 1); 14-day washout; then, the opposite therapy (period 2). Endpoints included weekly change in DPN pain score, sleep interference, adverse events, and patient-reported outcomes. RESULTS: Patients with similar baseline characteristics were randomized (period 1) to 1 of the 2 following possible sequences: pregabalin→placebo (n=154) or placebo→pregabalin (n=147). Results of the primary efficacy measure, mean weekly DPN pain at endpoint, showed no significant difference between pregabalin and placebo. However, 1 sensitivity analysis (mixed-model repeated measures) found greater pain score reductions with pregabalin than placebo at weeks 2 to 4 and overall (all P<0.05). One secondary endpoint analysis, mean treatment difference in DPN-related sleep interference, favored pregabalin over placebo (P=0.0009). Other sensitivity and secondary analyses were nonsignificant. Treatment-emergent adverse events were consistent with the known safety profile of pregabalin. DISCUSSION: Pregabalin (vs. placebo) showed overall improvements in sleep, pain reduction in 1 sensitivity analysis, and was well tolerated. Potential factors that may have confounded the ability to detect a treatment difference in DPN pain reduction (high placebo response, carryover effect, short washout period, or pregabalin dose) are discussed in the context of future studies.

Overview

Integrity signals

Registry

Crossref · 10.1097/ajp.0000000000000254

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

See all 25

Metadata

Authors
Raskin, P., Huffman, C., Yurkewicz, L., Pauer, L., Scavone, J. M., Yang, R., & Parsons, B.
Affiliations
Pfizer (United States) (US)
Venue
The Clinical Journal of Pain
Published
2016-03
Volume
32
Issue
3
Pages
203-210
ISSN
0749-8047 (ISSN-L)
OpenAlex
W2267474964
Cited by
25
References
30
Citations by year
2025: 1 · 2024: 2 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 2
FWCI
1.72
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Journal of Pain (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Keywords
pregabalin, diabetic neuropathic pain, nonsteroidal anti-inflammatory drugs, neuropathic pain, sleep interference, placebo response, residual effects, washout period, drug safety, crossover trial
MeSH terms
Pregabalin, Adult, Aged, Aged, 80 and over, Analgesics, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Diabetic Neuropathies, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Italy, Male, Middle Aged, Neuralgia, Pain Measurement, United States, Treatment Outcome, Czech Republic, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study. https://app.cochat.ai/papers/10.1097/ajp.0000000000000254
The paper
Raskin, P., Huffman, C., Yurkewicz, L., Pauer, L., Scavone, J. M., Yang, R., & Parsons, B. (2016). Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study. The Clinical Journal of Pain. https://doi.org/10.1097/ajp.0000000000000254

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.